Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality.
Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality. Euro Surveill. 2015;20(16) Authors: Savage RD, Winter AL, Rosella LC, Olsha R, Gubbay JB, Skowronski DM, Crowcroft NS PMID: 25953275 [PubMed - in process]
Scientists fear mass medication of livestock if the UK diverges from EU rules Related items fromOnMedica Doctors can help overcome ‘vaccine hesitancy’ NHS review recommends making childhood vaccination more 'convenient' for parents Point-of-care diagnostics needed to curb antimicrobial resistance Swine flu hits youngest most but mortality greatest in elderly Expert questions US advice on influenza vaccines
Date: Tuesday, 11 19, 2019; Speaker: Ian A. Wilson, D.Phil., D.Sc., Hanson Professor of Structural Biology , The Scripps Research Institute; Building: Building 10 (Clinical Center); Lipsett Amphitheater; Videocast Event
Results expected by end of 2020 JERUSALEM, Nov. 18, 2019 -- (Healthcare Sales &Marketing Network) -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficac... Biopharmaceuticals BiondVax Pharmaceuticals, influenza vaccine
This study demonstrates the usefulness of the HPAI H5N1 HA2 E29 epitope as a DIVA antigen in HPAI H5N1 vaccinated and infected chickens.Research Highlight E29 (HA2 position 488-516) epitope is antigenic in chickenAntibodies to E29 are elicited following live H5N1 virus infection in chickenE29 epitope is a potential DIVA antigen for use in ELISA. PMID: 31738584 [PubMed - as supplied by publisher]
(CNN) — The US Centers for Disease Control and Prevention told doctors on a conference call this week that the United States is seeing more flu than is typical for this time of year. “Influenza is off to an early start,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was on the CDC call, which included members of the Influenza Hospitalization Surveillance Network, a group of hospitals that help the CDC assess the severity of the flu season. Thirty states are seeing flu activity — for this time of year, that’s the most states in a decade. Three s...
Condition: Influenza Intervention: Drug: Flumist Quadrivalent Nasal Product Sponsor: University of Alabama at Birmingham Not yet recruiting
CONCLUSION: We report on an assay to measure stem-specific ADCC activity using SS np probes. Our results indicate high prevalence of HA-stem antibodies with cross-reactive ADCC activity. Such assay could be utilized in the assessment of next generation influenza vaccines. PMID: 31735504 [PubMed - as supplied by publisher]
CONCLUSIONS: A vaccination programme which targets children under 15 is predicted to have much larger epidemiological impact than those targeting elderly. PMID: 31735503 [PubMed - as supplied by publisher]
In this study, two conserved epitopes (NG-34 and CS-17) fused to flagellin were produced in a Baculovirus platform based on Trichoplusia ni larvae as living biofactories. Soluble extracts obtained from larvae expressing "flagellin-NG34/CS17 antigen" were used to immunize chickens and the efficacy of the vaccine was evaluated against a heterologous H7N1 HPAIV challenge in chickens. The flagellin-NG34/CS17 vaccine protected the vaccinated chickens and blocked viral shedding orally and cloacally. Furthermore, no apparent clinical signs were monitored in 10/12 vaccinated individuals. The mechanism of protection confe...
Conclusions: QIV was immunogenic against the additional B lineage strain (B Victoria) without significantly compromising the immunogenicity of the other three vaccine strains, therefore, adding a second B lineage strain in QIV could broaden protection against influenza B infection in this age group. As the QIV immunogenicity differed regarding the four antigens, formulation adjustments to increase the antigen concentration of the serotypes that have lower immunogenicity could increase effectiveness. Prior season vaccination was associated with lower antibody response to a new vaccine, although not consistent through the vaccine strains.